PLoS ONE · 2013 · 38 citations · 24 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryEnzymologyLead OptimizationAntibacterial PharmacologyEnzyme InhibitionLibrary ScreeningAromatic Carboxylic AcidsEnzyme Assay DevelopmentHigh-throughput Screening AssaysMycobacterium Tuberculosis InfectionMycobacterium Tuberculosis PathogenesisNovel Antibacterial Drug DiscoveryRecombinant Protein PurificationTuberculosis Drug Development
The enzyme pantothenate synthetase, PanC, is an attractive drug target in Mycobacterium tuberculosis. It is essential for the in vitro growth of M. tuberculosis and for survival of the bacteria in the mouse model of infection. PanC is absent from mammals. We developed an enzyme-based assay to identify inhibitors of PanC, optimized it for high-throughput screening, and tested a large and diverse library of compounds for activity. Two compounds belonging to the same chemical class of 3-biphenyl-4- cyanopyrrole-2-carboxylic acids had activity against the purified recombinant protein, and also inhibited growth of live M. tuberculosis in manner consistent with PanC inhibition. Thus we have identified a new class of PanC inhibitors with whole cell activity that can be further developed.
24
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Stewart T. Cole, Roland Brosch, Julian Parkhill et al. · Nature · 1998 · 7.9K citations · Full text
Platensimycin is a selective FabF inhibitor with potent antibiotic properties
Jun Wang, S.M. Soisson, Katherine Young et al. · Nature · 2006 · 815 citations